Loading clinical trials...
Loading clinical trials...
This is an open label, dose escalation study of ARQ 171 administered via intravenous infusion (IVI) into a peripheral vein weekly. Patients with advanced solid tumors, who are refractory to available...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
NCT04541381 · Gastrointestinal Cancer, Head and Neck Cancer, and more
NCT05468034 · Breast Cancer, Indolent Metastatic Breast Cancer
NCT06713993 · Esophageal Cancer (EsC)
NCT07489378 · Very Rare Tumors, Very Rare Cancers, and more
NCT01109420 · Non-Medullary Thyroid Cancer
Premiere Oncology
Santa Monica, California
Dana Farber/Harvard Cancer Center
Boston, Massachusetts
Mary Crowley Medical Research Center
Dallas, Texas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions